JB Chemicals & Pharmaceuticals Ltd. (IN:JBCHEPHARM)
:JBCHEPHARM
Top Page
JB Chemicals & Pharmaceuticals Ltd.
(JBCHEPHARM)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹2,222.00
▲(20.25% Upside)
Action:DowngradedDate:11/01/25
JB Chemicals & Pharmaceuticals Ltd. has a strong financial foundation with impressive revenue growth and profitability. However, the stock's valuation appears high, and technical indicators suggest a neutral market sentiment. The absence of earnings call insights and corporate events limits additional context.
Positive Factors
Material revenue expansion
A sustained jump in annual revenue provides a bigger base for investment and pricing leverage. Over 2-6 months this underpins stronger market presence, funds R&D or commercial expansion, and reduces dependence on single-product swings, supporting durable business growth.
Negative Factors
Capex volatility risks
Variable capital spending can create swings in free cash flow and limit the company's ability to consistently invest in capacity or return cash to shareholders. Over months this can tighten liquidity planning and constrain sequential investment or dividend stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Material revenue expansion
A sustained jump in annual revenue provides a bigger base for investment and pricing leverage. Over 2-6 months this underpins stronger market presence, funds R&D or commercial expansion, and reduces dependence on single-product swings, supporting durable business growth.
Read all positive factors
JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹330.39B
Dividend Yield0.86%
Average Volume (3M)2.67K
Price to Earnings (P/E)36.0
Beta (1Y)0.50
Revenue Growth10.25%
EPS Growth17.01%
CountryIN
Employees5,311
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.70
Shares Outstanding160,558,700
10 Day Avg. Volume4,569
30 Day Avg. Volume2,671
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.17
Price to Sales (P/S)6.28
P/FCF Ratio30.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)52.01
Revenue Forecast (FY)₹42.95B
JB Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, an...
How the Company Makes Money
JB Chemicals & Pharmaceuticals Ltd. makes money primarily by selling pharmaceutical products, with revenues typically generated through (1) domestic branded formulations sold in India via prescription-led marketing and distribution to hospitals, p...
JB Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.92B | 39.18B | 34.84B | 31.17B | 24.24B | 20.06B |
| Gross Profit | 25.24B | 26.01B | 13.46B | 11.14B | 15.61B | 12.88B |
| EBITDA | 11.26B | 10.32B | 9.33B | 7.04B | 5.82B | 6.72B |
| Net Income | 7.18B | 6.60B | 5.53B | 4.10B | 3.85B | 4.48B |
Balance Sheet | ||||||
| Total Assets | 47.12B | 42.74B | 39.94B | 35.54B | 26.07B | 22.38B |
| Cash, Cash Equivalents and Short-Term Investments | 9.01B | 4.50B | 4.60B | 2.69B | 566.50M | 6.94B |
| Total Debt | 409.10M | 278.90M | 3.78B | 5.72B | 545.59M | 449.88M |
| Total Liabilities | 9.07B | 8.40B | 10.71B | 10.74B | 4.69B | 4.25B |
| Stockholders Equity | 38.06B | 34.33B | 29.23B | 24.80B | 21.34B | 18.10B |
Cash Flow | ||||||
| Free Cash Flow | 3.16B | 8.05B | 5.39B | -1.39B | -5.37B | 2.67B |
| Operating Cash Flow | 3.62B | 9.02B | 8.01B | 6.26B | 1.70B | 3.15B |
| Investing Cash Flow | -2.98B | -2.96B | -4.08B | -9.62B | 23.20M | -2.31B |
| Financing Cash Flow | -863.90M | -5.80B | -3.41B | 3.57B | -1.38B | -874.23M |
JB Chemicals & Pharmaceuticals Ltd. Technical Analysis
Positive
1847.80
Price Trends
1982.54
Positive
1883.92
Positive
1785.02
Positive
Market Momentum
28.01
Positive
50.22
Neutral
14.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JBCHEPHARM, the sentiment is Positive. The current price of 1847.8 is below the 20-day moving average (MA) of 2089.93, below the 50-day MA of 1982.54, and above the 200-day MA of 1785.02, indicating a neutral trend. The MACD of 28.01 indicates Positive momentum. The RSI at 50.22 is Neutral, neither overbought nor oversold. The STOCH value of 14.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JBCHEPHARM.
JB Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹352.50B | 31.59 | ― | 1.04% | 10.74% | 11.91% | |
69 Neutral | ₹214.47B | 40.22 | ― | 0.69% | 6.13% | 35.83% | |
66 Neutral | ₹330.39B | 36.01 | ― | 0.86% | 10.25% | 17.01% | |
61 Neutral | ₹284.82B | 27.13 | ― | 1.07% | -1.51% | 14.27% | |
53 Neutral | ₹612.52B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,057.75
452.52
28.19%
IN:AJANTPHARM
Ajanta Pharma Limited
2,821.45
234.65
9.07%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,653.60
579.27
53.92%
IN:GLAND
Gland Pharma Ltd.
1,728.75
188.05
12.21%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,170.50
665.44
44.21%
IN:PFIZER
PFIZER LIMITED
4,688.15
765.13
19.50%
JB Chemicals & Pharmaceuticals Ltd. Corporate Events
JB Chemicals Publishes NCLT-Directed Notice for Equity Shareholders’ Meeting
Mar 28, 2026
JB Chemicals Pharmaceuticals Ltd. has notified the stock exchange that it has published a newspaper advertisement giving notice of a meeting of its equity shareholders. The shareholder meeting has been convened pursuant to an order dated March 23...
JB Chemicals & Pharmaceuticals Publishes Postal Ballot Notices for Shareholders
Feb 23, 2026
JB Chemicals Pharmaceuticals has notified the stock exchange that it has published newspaper advertisements related to a postal ballot process for its shareholders. The notices, carried in the English and Gujarati editions of the Financial Expres...
JB Chemicals seeks shareholder nod for board overhaul via e-voting
Feb 20, 2026
JB Chemicals Pharmaceuticals has launched a postal ballot process seeking shareholder approval for several board appointments, including elevating Aman Mehta to director and managing director. The exercise also covers the induction of Amal Kelshi...
JB Chemicals & Pharmaceuticals Announces Resignations of Two Senior Presidents
Feb 5, 2026
JB Chemicals Pharmaceuticals Ltd. has announced that two key senior management executives, President – Operations Kunal Khanna and President (India Business) Dilip Singh Rathore, have tendered their resignations effective from the close of ...
JB Chemicals & Pharmaceuticals Announces Resignation of Two Senior Presidents
Feb 5, 2026
JB Chemicals Pharmaceuticals Ltd. has announced the resignations of two senior executives, Mr. Kunal Khanna, President – Operations, and Mr. Dilip Singh Rathore, President (India Business), effective from the close of business on March 5, 2...
JB Chemicals & Pharmaceuticals Shifts Registered Office from Maharashtra to Gujarat
Feb 4, 2026
JB Chemicals Pharmaceuticals Ltd. has shifted its registered office from the state of Maharashtra to the state of Gujarat, with the new location now at 302, Iscon Mall, Star India Bazar Building, Opp. Jodhpur BRTS Satellite, Ahmedabad-380015. The...
JB Chemicals Clarifies Date on Promoter Reclassification Request Filing
Jan 21, 2026
JB Chemicals Pharmaceuticals Ltd. has issued a corrigendum clarifying that a request from shareholder Tau Investment Holdings Pte. Ltd. for reclassification from ‘Promoter’ to ‘Public’ under Indian listing regulations was ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.